|
Mr. Enright, 45, has served as a director since June 2006. Mr. Enright is a founder and Managing Director of Longitude Capital, a life sciences venture capital firm specializing in medical devices and biotechnology. From 2002 through 2006, Mr. Enright was a Managing Director of Pequot Ventures, the direct venture investment arm of Pequot Capital Management, Inc., and has been a member of various general partnerships of Pequot’s venture capital and private equity funds since June 2002. Mr. Enright is currently a consultant for Pequot Capital Management, Inc. From 1998 to 2001, Mr. Enright was a Managing Member of Diaz & Atschul Group, LLC, a principal investment group. From 1995 to 1998, he served in various executive positions at Valentis, Inc., a biotechnology company engaged in the development of products for peripheral arterial disease, including as Senior Vice President, Corporate Development, and Chief Financial Officer. From 1993 to 1994, he was Senior Vice President of Finance and Business Development for Boehringer Mannheim Therapeutics, a pharmaceutical company and a subsidiary of Corange Ltd. From 1989 to 1993, Mr. Enright was employed at PaineWebber Incorporated, an investment banking firm, where he became a Vice President in 1992. Mr. Enright currently serves on the boards of Threshold Pharmaceuticals, Inc., DiObex, Codexis, Horizon Therapeutics, MAP Pharmaceuticals, Prestwick Pharmaceuticals, Raven biotechnologies and InfaCare Pharmaceuticals. Mr. Enright earned a B.S. in Biological Sciences from Stanford University and a M.B.A. from the Wharton School of Business at the University of Pennsylvania. | 